Alison Turner
About
Alison Turner is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Alison Turner has authored 24 papers receiving a total of 218 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 11 papers in Molecular Biology and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Alison Turner's work include PI3K/AKT/mTOR signaling in cancer (5 papers), Ovarian cancer diagnosis and treatment (4 papers) and Lung Cancer Treatments and Mutations (4 papers). Alison Turner is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (5 papers), Ovarian cancer diagnosis and treatment (4 papers) and Lung Cancer Treatments and Mutations (4 papers). Alison Turner collaborates with scholars based in United Kingdom, Australia and Switzerland. Alison Turner's co-authors include K. Brownlee, J T Brocklebank, Simon J. Newell, Lawrence Miall, Michael Henderson, Victoria Allgar, John Shaw, Judith L. Black, Mona Parmar and Udai Banerji and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PEDIATRICS.
In The Last Decade
Alison Turner
23 papers receiving 210 citations
Peers
Alison Turner
Motoharu Hamada Japan
Stéphanie De Rechter Belgium
Shinya Ishiko Japan
Carolina Conte Italy
Kristen Whitaker United States
Keri A. Drake United States
Amy Fearn United Kingdom
Angela C. Chen United States
Fangrui Ding China
H. Randall Craig United States
Citations per year, relative to Alison Turner Alison Turner (= 1×)
peers
Motoharu Hamada
Countries citing papers authored by Alison Turner
Since
Specialization
Citations
This map shows the geographic impact of Alison Turner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alison Turner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alison Turner more than expected).
Fields of papers citing papers by Alison Turner
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Alison Turner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alison Turner. The network helps show where Alison Turner may publish in the future.
Co-authorship network of co-authors of Alison Turner
This figure shows the co-authorship network connecting the top 25 collaborators of Alison Turner. A scholar is included among the top collaborators of Alison Turner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alison Turner. Alison Turner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Welsh, Liam, Anna Zachariou, Mona Parmar, et al.. (2023). Abstract CT093: Preliminary evidence of antitumor activity of Ipatasertib (Ipat) and Atezolizumab (A) in glioblastoma (GBM) patients (pts) with PTEN loss in the Phase 1 Ice-CAP trial (NCT03673787). Cancer Research. 83(8_Supplement). CT093–CT093.
2.
Guo, Christina, Simon J. Crabb, Simon Pacey, et al.. (2023). A phase (Ph) I/II trial of abiraterone acetate in combination with tildrakizumab (anti-IL23 monoclonal antibody) in patients with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 41(16_suppl). TPS5105–TPS5105.
3.
Rodney, Simon, Lisa Pickard, Mona Parmar, et al.. (2023). Abstract 3461: Preclinical and clinical evaluation of the RAF/MEK clamp avutometinib (VS-6766) in combination with the mTOR inhibitor everolimus for the treatment of KRAS mutated non-small cell lung cancer. Cancer Research. 83(7_Supplement). 3461–3461.
4.
Minchom, Anna, Christina Guo, Nina Tunariu, et al.. (2022). Phase I trial of the RAF/MEK clamp VS-6766 in combination with everolimus using an intermittent schedule with expansion in NSCLC across multiple KRAS variants.. Journal of Clinical Oncology. 40(16_suppl). 9018–9018.
5.
Banerjee, Susana, João Paulo da Silveira Nogueira Lima, Matthew Krebs, et al.. (2021). 725MO Phase I study of the combination of the dual RAF/MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Results of efficacy in low grade serous ovarian cancer. Annals of Oncology. 32. S728–S728.
6.
Lopez, Juanita, Malaka Ameratunga, Anna Minchom, et al.. (2019). PIPA: A phase Ib study of selective ß-isoform sparing phosphatidylinositol 3-kinase (PI3K) inhibitor taselisib (T) plus palbociclib (P) in patients (pts) with advanced solid cancers—Safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the doublet combination.. Journal of Clinical Oncology. 37(15_suppl). 3087–3087.
7.
Pascual, Javier, Iain R. Macpherson, Anne Armstrong, et al.. (2019). PIPA: A phase Ib study of β-isoform sparing phosphatidylinositol 3-kinase (PI3K) inhibitor taselisib (T) plus palbociclib (P) and fulvestrant (FUL) in PIK3CA-mutant (mt) ER-positive and taselisib (T) plus palbociclib (P) in PIK3CA-mutant (mt) ER-negative advanced breast cancer.. Journal of Clinical Oncology. 37(15_suppl). 1051–1051.
8.
Krebs, Matthew, James Spicer, Nicola Steele, et al.. (2017). P3.02c-003 TAX-TORC: The Novel Combination of Weekly Paclitaxel and the Dual mTORC1/2 Inhibitor AZD2014 for the Treatment of Squamous NSCLC. Journal of Thoracic Oncology. 12(1). S1272–S1273.
9.
Chénard-Poirier, Maxime, Martin Kaiser, Kevin Boyd, et al.. (2017). Results from the biomarker-driven basket trial of RO5126766 (CH5127566), a potent RAF/MEK inhibitor, in RAS- or RAF-mutated malignancies including multiple myeloma.. Journal of Clinical Oncology. 35(15_suppl). 2506–2506.
10.
Lim, Joline S.J., Uzma Asghar, Nikolaos Diamantis, et al.. (2017). A phase I trial of selective PI3K inhibitor taselisib (tas) plus palbociclib (palb) with and without endocrine therapy incorporating pharmacodynamic (PD) studies in patients (pts) with advanced cancers.. Journal of Clinical Oncology. 35(15_suppl). 2573–2573.
11.
Banerji, Udai, Alvaro Ingles Garces, Vasiliki Michalarea, et al.. (2017). An investigator-initiated phase I study of ONX-0801, a first-in-class alpha folate receptor targeted, small molecule thymidylate synthase inhibitor in solid tumors.. Journal of Clinical Oncology. 35(15_suppl). 2503–2503.
12.
Harris, S.J., Maria J. de Miguel, Mona Parmar, et al.. (2016). Updated efficacy and safety results from the phase I study of intermittent dosing of the dual MEK/RAF inhibitor, RO5126766 in patients (pts) with RAS/RAF mutated advanced solid tumours.. Journal of Clinical Oncology. 34(15_suppl). 2582–2582.
13.
Basu, Bristi, Alison Turner, Emma Hall, et al.. (2015). Abstract CT138: Translating preclinical observations to the clinic: Combination of the dual m-TORC1/2 inhibitor AZD2014 and paclitaxel in ovarian and lung cancer. Cancer Research. 75(15_Supplement). CT138–CT138.
14.
Roda, Desamparados, Han Hsi Wong, Elena Geuna, et al.. (2014). TAX-TORC: A phase I trial of the combination of AZD2014 (dual mTORC1/mTORC2 inhibitor) and weekly paclitaxel in patients with solid tumors.. Journal of Clinical Oncology. 32(15_suppl). 2607–2607.
15.
Miall, Lawrence, Michael Henderson, Alison Turner, et al.. (1999). Plasma Creatinine Rises Dramatically in the First 48 Hours of Life in Preterm Infants. PEDIATRICS. 104(6). e76–e76.
16.
James, Sharon Y., Alison Turner, & Kay W. Colston. (1997). Induction of Apoptosis in Human Leukaemia Cells is Differentially Regulated by Vitamin D Derivatives and Retinoids. Hematology. 2(4). 289–301.
17.
Grant, Steven, Alex J. Freemerman, Alison Turner, et al.. (1995). Induction of apoptotic DNA fragmentation and c-jun downregulation in human myeloid leukemia cells by the permeant Ca2+ chelator BAPTA/AM.. PubMed. 7(7-8). 381–92.
18.
Turner, Alison, et al.. (1987). Studies on alpha adrenoceptors in guinea-pig peripheral lung strips. Naunyn-Schmiedeberg s Archives of Pharmacology. 335(3). 269–73.
19.
Turner, Alison, J. Paul Seale, & John Shaw. (1983). Antigen sensitization does not alter response of guinea-pig lung strips to noradrenaline. European Journal of Pharmacology. 87(1). 141–144.
20.
Black, Judith L., Alison Turner, & John Shaw. (1981). α-adrenoceptors in human peripheral lung. European Journal of Pharmacology. 72(1). 83–86.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Motoharu Hamada Breakdown of academic impact, for papers by Stéphanie De Rechter Breakdown of academic impact, for papers by Shinya Ishiko Breakdown of academic impact, for papers by Carolina Conte Breakdown of academic impact, for papers by Kristen Whitaker Breakdown of academic impact, for papers by Keri A. Drake Breakdown of academic impact, for papers by Amy Fearn Breakdown of academic impact, for papers by Angela C. Chen Breakdown of academic impact, for papers by Fangrui Ding Breakdown of academic impact, for papers by H. Randall Craig